{
    "organizations": [],
    "uuid": "a61dbc4b89c087f5e9ad30b0684fe0a1ab7c4704",
    "author": "",
    "url": "https://www.reuters.com/article/brief-seattle-genetics-and-pieris-pharma/brief-seattle-genetics-and-pieris-pharmaceuticals-announce-multi-program-immuno-oncology-collaboration-idUSFWN1PZ0XU",
    "ord_in_thread": 0,
    "title": "BRIEF-Seattle Genetics And Pieris Pharmaceuticals Announce Multi-Program Immuno-Oncology Collaboration",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 52 AM / Updated 8 minutes ago BRIEF-Seattle Genetics And Pieris Pharmaceuticals Announce Multi-Program Immuno-Oncology Collaboration Reuters Staff \nFeb 9 (Reuters) - Pieris Pharmaceuticals Inc: \n* SEATTLE GENETICS AND PIERIS PHARMACEUTICALS ANNOUNCE MULTI-PROGRAM IMMUNO-ONCOLOGY COLLABORATION \n* SEATTLE GENETICS INC - ‍SEATTLE GENETICS WILL PAY PIERIS A $30 MILLION UPFRONT FEE, TIERED ROYALTIES ON NET SALES UP TO LOW DOUBLE-DIGITS​ \n* SEATTLE GENETICS - CO, PIERIS TO EVALUATE BISPECIFIC IMMUNO-ONCOLOGY AGENTS COMBINING PIERIS’ ANTICALIN TECHNOLOGY WITH SOME OF CO‘S CANCER-TARGETED ANTIBODIES \n* SEATTLE GENETICS - UNDER TERMS OF AGREEMENT CO TO PAY PIERIS UP TO $1.2 BILLION IN TOTAL SUCCESS-BASED PAYMENTS ACROSS THREE PRODUCT CANDIDATES \n* SEATTLE GENETICS INC - ‍SEATTLE GENETICS WILL SOLELY DEVELOP, FUND AND COMMERCIALIZE OTHER TWO PROGRAMS​ \n* SEATTLE GENETICS-PIERIS PHARMA, CO HAVE ENTERED INTO AGREEMENT FOR DEVELOPING MULTIPLE TARGETED BISPECIFIC IMMUNO-ONCOLOGY TREATMENTS FOR BLOOD CANCERS \n* SEATTLE GENETICS INC - ‍PRIOR TO INITIATION OF A PIVOTAL TRIAL, PIERIS MAY OPT INTO GLOBAL CO-DEVELOPMENT AND U.S. COMMERCIALIZATION OF SECOND PROGRAM​ \n* SEATTLE GENETICS - PRIOR TO INITIATION OF PIVOTAL TRIAL, PIERIS MAY OPT FOR A SHARE IN GLOBAL COSTS, PROFITS ON 50/50 BASIS FOR SECOND PROGRAM Source text for Eikon: Further company coverage:",
    "published": "2018-02-09T13:50:00.000+02:00",
    "crawled": "2018-02-09T14:04:26.009+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "updated",
        "minute",
        "ago",
        "genetics",
        "pieris",
        "pharmaceutical",
        "announce",
        "collaboration",
        "reuters",
        "staff",
        "feb",
        "reuters",
        "pieris",
        "pharmaceutical",
        "inc",
        "seattle",
        "genetics",
        "pieris",
        "pharmaceutical",
        "announce",
        "collaboration",
        "seattle",
        "genetics",
        "inc",
        "genetics",
        "pay",
        "pieris",
        "million",
        "upfront",
        "fee",
        "tiered",
        "royalty",
        "net",
        "sale",
        "low",
        "seattle",
        "genetics",
        "co",
        "pieris",
        "evaluate",
        "bispecific",
        "agent",
        "combining",
        "pieris",
        "anticalin",
        "technology",
        "co",
        "antibody",
        "seattle",
        "genetics",
        "term",
        "agreement",
        "co",
        "pay",
        "pieris",
        "billion",
        "total",
        "payment",
        "across",
        "three",
        "product",
        "candidate",
        "seattle",
        "genetics",
        "inc",
        "genetics",
        "solely",
        "develop",
        "fund",
        "commercialize",
        "two",
        "seattle",
        "pharma",
        "co",
        "entered",
        "agreement",
        "developing",
        "multiple",
        "targeted",
        "bispecific",
        "treatment",
        "blood",
        "cancer",
        "seattle",
        "genetics",
        "inc",
        "initiation",
        "pivotal",
        "trial",
        "pieris",
        "may",
        "opt",
        "global",
        "commercialization",
        "second",
        "seattle",
        "genetics",
        "prior",
        "initiation",
        "pivotal",
        "trial",
        "pieris",
        "may",
        "opt",
        "share",
        "global",
        "cost",
        "profit",
        "basis",
        "second",
        "program",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}